Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease

Osteoporosis International

Volumn 16, Issue 12, 2005, Pages 1727-1730

  Cremers, Serge C L M ^a   Van Hogezand, Ruud ^a   Bänffer, Denise ^a   Hartigh, Janden ^a   Vermeij, Pieter ^a   Papapoulos, Socrates E ^a   Hamdy, Neveen A T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Absorption; Bisphosphonates; Crohn's disease; Osteoporosis; Pharmacokinetics

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; COLLAGEN; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; CROSS LINKING; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG URINE LEVEL; EVALUATION; FEMALE; HUMAN; INTESTINE ABSORPTION; INTESTINE RESECTION; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; URINARY EXCRETION;

ABSORPTION; ADMINISTRATION, ORAL; ALENDRONATE; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFEDIOL; CALCIUM, DIETARY; COLLAGEN; COLLAGEN TYPE I; CREATININE; CROHN DISEASE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; TREATMENT OUTCOME; VITAMIN D;

EID: 29044442910     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1911-7     Document Type: Article

References (16)

1. Bisschoff SC, Herrmann A, Goeke M, Manns MP, von zur Muehlen A, Brabant G (1997) Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 92:1157-1163
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 280:2077-2082
3. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
4. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 604:604-610
5. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H et al (1995) Studies on the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
6. Mitchell DY, Eusebio RA, Dunlap LE, Pallone KA, Nesbitt JD, Russell DA et al (1998) Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 15:228-232
7. Lin JH (1996) Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75-85
8. Leder BZ, Kronenberg HM (2000) Gastroenterologists and choosing the right bisphosphonate. Gastroenterology 119:866-869
9. Haderslev KV, Tjellesen L, Sorensen HA, Staun M (2000) Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119:639-646
10. Sparidans RW, den Hartigh J, Beijnen JH, Vermeij P (1998) Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. J Chromatogr B Biomed Sci Appl 705:331-339
11. Sparidans RW, den Hartigh J, Cremers SCLM, Beijnen JH, Vermeij P (1999) Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. J Chromatogr B Biomed Sci Appl 730:95-99
12. Gubbins PO, Bertch KE (1991) Drug absorption in gastrointestinal disease and surgery. Clin Pharmacokinet 21:431-447
13. Cremers SCLM, Sparidans RW, den Hartigh J, Hamdy NAT, Vermeij P, Papapoulos SE (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883-890
14. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS et al (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis - A double-blind, randomized, controlled trial. Ann Intern Med 128:253-261
15. Garnero P, Darte C, Delmas PD (1999) A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24:603-609
16. Adachi JD, Saag KG, Delmas PD et al (2001)Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-11